Rossari Biotech Limited announced its financial results for the quarter ended June 30, 2026 (Q1 FY27) through a regulatory filing to BSE Limited and National Stock Exchange of India Limited.

Financial Performance - Consolidated Basis

  • Revenue from operations: ₹697.2 crore, up 28% YoY from ₹543.7 crore in Q1 FY26
  • EBITDA: ₹80.6 crore, up 19% YoY from ₹67.9 crore
  • EBITDA margin: 11.6% compared to 12.5% in Q1 FY26
  • PAT: ₹35.1 crore, up 4% YoY from ₹33.6 crore
  • EPS (Diluted): ₹6.3 (not annualized) compared to ₹6.1 in Q1 FY26

Financial Performance - Standalone Basis

  • Revenue from operations: ₹482.3 crore, up 32% YoY from ₹365.8 crore
  • EBITDA: ₹56.4 crore, up 28% YoY from ₹43.9 crore
  • EBITDA margin: 11.7% compared to 12.0% in Q1 FY26
  • PAT: ₹34.3 crore, up 31% YoY from ₹26.2 crore
  • EPS (Diluted): ₹6.2 compared to ₹5.8 in Q1 FY26

Business Segment Performance

All business segments showed strong growth:

  • Home, Personal Care and Performance Chemicals (HPPC): 28% YoY growth
  • Textile Specialty Chemicals (TSC): 28% YoY growth
  • Animal Health and Nutrition (AHN): 27% YoY growth

Key Developments

Thailand Greenfield Facility:

  • Established through subsidiary Unistar Thai
  • Blending facility with installed capacity of 5,000 MTPA
  • Capabilities across powders, granules and liquids
  • Designed to serve Southeast Asia market with customized formulations
  • Aims to improve supply-chain efficiency and respond to local market requirements

Non-Core Asset Monetization:

  • Completed sale of Andheri office during the quarter
  • Follows sale of Kanjurmarg office in previous quarter
  • Part of ongoing monetization of non-core assets

Management Commentary

Mr. Edward Menezes (Promoter & Executive Chairman) and Mr. Sunil Chari (Promoter & Managing Director) stated that growth was driven by healthy domestic business momentum and continued international expansion. They highlighted the company's diversified business model, broad-based market presence, and disciplined execution. The management emphasized focus on driving optimal utilization of recent capacity investments, strengthening product portfolio, and enhancing operational efficiencies.